Healthcare Industry News:  breast cancer 

Devices Oncology Surgery

 News Release - November 12, 2015

IntraOp Completes Delivery of IntraOp(R) Mobetron(R) Electron IORT System to Nanjing General Hospital

From treating breast to pancreatic, to colorectal, and beyond, Mobetron continues to be the leading IORT technology in China with it first installation in the Jiangsu Province

SUNNYVALE, Calif., Nov. 12, 2015 -- (Healthcare Sales & Marketing Network) -- IntraOp Medical Corporation today announced its ninth installation in China, the world's most populated country and second largest economy. IntraOp®, the developer and manufacturer of the Mobetron®, an electron based intraoperative radiation therapy (IORT) device, has been providing life-saving cancer treatment technology to leading healthcare institutions worldwide for more than 20 years.

Nanjing General Hospital (NGH) has officially become the ninth hospital in China to install the Mobetron and the first in Jiangsu Province. NGH joins other leading China institutions such as 301 Beijing General Hospital, Chinese Academy of Medical Science (CAMS) and Shanghai Tumor Hospital in bringing IntraOp's innovative Mobetron to cancer patients in China.

"We are delighted to be the first hospital in Jiangsu province to install a Mobetron and make this advanced technology available to patients in the region," said Dr. Zhu Xixu, Director of the Department of Radiation Oncology at NGH. "Electron IORT has demonstrated significant benefits in the treatment of locally advanced and recurrent cancers as well early stage breast cancer. The Mobetron expands our ability to treat these cancers and ensures our patients have access to the best possible treatment options to aid their fight against cancer."

"For more than a decade, Mobetron has been the leading IORT technology in China and we are honored to be adding NGH to our network of hospitals there. Expanding the availability of electron IORT to Chinese physicians and their patients suffering a variety of cancers is a top priority for IntraOp," said IntraOp CEO Bruce Khouri. "We are committed to advancing the standard of care for cancer treatment with the Mobetron, the world's only self-shielded, portable LINAC device designed to deliver precise, targeted doses of cancer killing radiation during surgery," Khouri added.

About IntraOp Medical Corporation

IntraOp® is the leading innovator of electron radiation devices for treating cancer as an adjunct to invasive surgical procedures. As the developer and manufacturer of the Mobetron®, IntraOp pioneered the world's first portable, self-shielded LINAC used for Intraoperative Radiation Therapy (IORT). Mobetron IORT is capable of delivering a precise dose of cancer killing electrons to any clinical target during surgery, when healthy tissue is not involved and cancer cells are most vulnerable. More than 15,000 patients in 16 countries have benefited from Mobetron IORT. Based in Sunnyvale, California, IntraOp is a cancer care company uniting radiation and surgical oncology in the fight against cancer. For more information please visit: intraop.com


Source: IntraOp Medical

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.